AAD see adjoint algorithmic differentiation
actual recovery 274
add-on 154, 206, 368
additional termination event (ATE) 62–4, 72
additional value adjustment (AVA) 182–3
adjoint algorithmic differentiation (AAD) 414
adverse selection 201
aggregation 215, 237
AIG see American International Group
AIGFP 73
Albanese, C. 351, 355
Altman, E. 267, 268
AMBAC 191, 192
American International Group (AIG) 1, 7, 8, 9, 72, 73, 99, 162, 187, 191
American Monte Carlo methods 214, 323, 365, 413–14
amortisation 248–9
Arvanitis, A. 236
Ashanti 99
Asian crisis (1997) 3, 379
asset correlation multiplier 162
asymmetric funding 350
ATE see additional termination event
AVA see additional value adjustment
backloading 430–3, 440–1
backtesting 22–3, 162, 164–6, 413
Bankhaus Herstatt 27
banks
bailouts 1, 3
counterparty risk 4, 32
crisis in 6–8
and DVA 9
funding costs 285, 286–9, 336
funding liquidity issues 100
and perfect collateralisation 297
runs on 5–6
too big to fail 1, 7, 187
Basel Committee on Banking Supervision (BCBS) 3–4, 114, 119, 145, 146, 148, 155, 162, 165, 169, 172, 177n, 180, 181, 270
Basel I framework 18, 144
Basel II framework 1, 4, 8, 19, 145, 146–7
Basel III framework 1, 40, 43, 63, 82, 96, 97, 143–4, 198, 249, 263, 270, 276, 350–1, 366, 379, 398, 399, 407, 413, 418
backtesting 164–6
increased margin period of risk 163–4
overview 161–3
stress testing 167–8
stressed EPE 163
wrong-way risk 166–7
BCBS see Basel Committee on Banking Supervision
BCVA see bilateral CVA
Bear Stearns 5–6, 8, 187
beta mapping 284
bid-offer spreads 33
bifurcations 201
bilateral 362, 365
derivative market 199
exposure 110
netting 52
OTC derivatives 57–8, 70, 84, 153
rules 1, 2
trades 196
bilateral collateral posting 89
bilateral collateral rules 8, 9, 29, 73, 74, 88, 285, 297
bilateral CVA (BCVA) 326, 327–8, 350
close-out 328–9
close-out amount 329
default correlation 328
eample 330–1
market quotation 329
survival 328
see also credit value adjustment (CVA)
BIS 176
Bliss, R.R. 90
Bollier, T.F. 206
bonds 119, 267
break clauses
cliff-edge effects 63
break clauses (continued)

determination of valuation 63
modelling difficulty 64
relationship issues 63–4
risk-reducing benefit 63
weaknesses in credit ratings 63

Brennan, M.J. 394
Brigo, D. 318, 329
Brouwer, D.P. 59
Brownian bridge 323
Burgard, C. 341, 351, 353, 355

calculation agent 81
Canabarro, E. 152n
capital 9, 43, 398, 422
charges 1
costs 33, 288–9, 423
metric 423
pricing 423
relief 276, 372, 402, 407–10

capital asset pricing model (CAPM) 227n, 288, 370

capital requirements 4, 143–4
Basel III 161–8
comparison of EAD methods 157–61
current exposure method (CEM) 148–50
double default 145–6
exposure at default (EAD) 146–8
increased 285
incurred CVA 148
internal model method (IMM) 151–3
internal ratings-based approach (IRB) 144–5
rational 168–80
regulatory changes 180–3
standardised approach 144, 153–7

capital value adjustment (KVA) 2, 10, 29, 45, 71, 73, 181, 202, 203, 288, 298, 359, 365, 367, 401, 422, 431, 433, 440
behavioural aspects 371–2
capital profiles 368–9
formula 369–70
incentives 375
management 375
overlaps and hedging 374–5
rationale 366–8
regulatory change 371–2
return on capital 375
term structure behaviour 370–1

Carver, L. 353, 374
cashflow differential 114–15
cashflows 47–8
floating 121–2
and MPR discretisation 250–1
periodic 120–5
Castagna, A. 353
CCDS see contingent CDS
CCP see central counterparty
CDO tranches 155
CDOs see collateralised debt obligations
CDPC see credit derivative product company
CDS see credit default swap
CE see current exposure
CEM see current exposure method
central clearing 365, 393–4
CCP 299
direct 299
indirect 299
mandate 1, 179
OTC derivative market 199
rules 29
central counterparty (CCP) 9, 29, 58, 70, 71, 96, 185, 186, 192–3, 286, 299, 360, 440–1
advantages/disadvantages 200–1
adverse selection 201
bifurcation 201
bilateral vs central clearing 199
capital charges 201–2
clearing mandate 193
default management 200
and interconnectedness 195
landscape 195–6
legal/operational efficiency 200
and liquidity 200
and loss mutualisation 200
moral hazard 200
and offsetting 200
OIS discounting 295
OTC clearing 193–5
procyclicality 201
risk management 196–9
and transparency 195, 200
and wrong-way risk 393–4
and xVA 202–3

Cesari, G. 214, 323, 413
cheapest-to-deliver option 89, 304
Chicago Mercantile Exchange (CME) 193
Chourdakis, K. 284
counterparty risk intermediation (continued)
derivative product companies 188–90
monolines 190–2
special purpose vehicles (SPV) 187–8
too big to fail 187
Counterparty Risk Management Policy Group (CRMPG) 3, 8
counterparty risk reduction 137
coupon blending 58
coupons 83
Coval, J. 394
credit 155
derivatives 128
limits 36–8
migration 34–5
quality 77–8, 436–7
ratings 63
wraps 190
credit curve mapping 275
and capital relief 276
CDS market 276–8
general approach 278–80
hedging 275–6
liquidity 275
loss given default 278
reference instrument 275
region 275
seniority 275
tenor 275
credit default swap (CDS) 6, 9, 10, 13, 16, 28, 36, 57, 61, 64, 163, 173, 267, 270, 274, 341, 379, 408
credit curve mapping 275–6
market 276–8
credit derivative product company (CDPC) 190–2
credit exposure 33–4, 56, 79–80
bilateral 110
close-out amount 111
comparisons to value-at-risk (VAR) 113–14
definition 109–11
link to funding 136
effective expected positive exposure (EEPE) 118–19
expected exposure (EE) 116
expected future value (EFV) 114–15
expected positive exposure (EPE) 117–18
factors driving exposure 119–28
impact of collateral 133–5, 138–41
impact of netting 129–33
impact of segregation/rehypothecation 136–8
initial margin 262–5
margin period of risk 247–51
metrics 114–19
modelling approach 246
negative 118
numerical examples 252–62
potential future exposure 115, 116–17
short option position 111–12
credit risk 19, 69
credit risk capital requirements see capital requirements
credit risk warehousing 402
credit spread 34–5, 219
credit spread impact 315–16
credit support amount 70, 78–9
credit support annex (CSA) 70–1, 138, 158, 335, 343
bilateral documentation 71
change of terms 337
non-financial clients 99
one-way agreement 72, 345
two-way agreement 72, 77, 79, 345
types 71–3
credit value adjustment (CVA) 2, 4–5, 7, 8, 9, 10, 22, 29, 30, 38, 44, 53, 71, 73, 100, 203, 298, 342, 370, 401, 425, 426, 432
accounting 40
allocation and pricing 317–23
Basel III 40
with collateral 323–5, 391
counterparty level 39
credit spread impact 315–16
defined 39–41
formula 311–12
history of 310–11
incremental 317–19
marginal 319–21
market practice 40
netting 317–19
numerical issues 321–3
recovery impact 316–17
regulators’ opinions 40
risk-neutral default probability 39–40, 269–70
risk-neutrality 314–15
stress-testing 167
Index 461

symmetric 350
trade level 38–9
see also bilateral CVA; CVA capital charge
CRMPG see Counterparty Risk Management Policy Group
cross-currency swaps 29–30, 31, 64–5, 125, 241, 308, 320, 370
cross-gamma 406–7
cross-product netting 52–3, 308
cross-sectional approach 283–4
CSA see credit support annex
CSA renegotiation 297
current exposure (CE) 149–50
current exposure method (CEM) 147, 148, 158, 205, 368, 368–9, 372–3, 426
add-ons 148–9
collateral treatment 149–50
netting 149–50
CVA see credit value adjustment
CVA capital charge 162, 168–9
advanced approach 171–4
calculation example 174–6
cost 177
criticisms 176–8
de-recognition of DVA 177
European exemptions 178–80
exemption 144, 180
IMM approval negative feedback loops 178
procyclicality 177
recognition of hedges 177
specific risk approval standardised formula 169–71
US implementation 178
see also credit value adjustment
CVA challenger model 270
CVA desk see xVA desk

Das, S. 226
De Prisco, B. 386
debt value adjustment (DVA) 2, 5, 8, 9, 10, 40, 44, 298, 335, 338–9, 341, 401, 422, 425, 426, 429
accounting standards 326–7
bilateral CVA formula 327–8
close-out and default correlation 328–31
close-out process 332
de-recognition 177
defaulter pays 393–4
default 49–50, 332
correlation 328
default probability 34–5
loss given default 273–5
real-world 267–9
risk-neutral 271–2, 267–70
term structure 272–3
defaulter pays 393–4
delivery vs payment (DVP) 27
delta-neutral hedge 408
derivative product companies (DPCs) 185, 186, 188–90
derivative risks 18
counterparty 20
cost 177
credit 19
integration of types 20
legal 19
liquidity 20
market 18–19
operational 19
derivatives 186
background 11–12
credit 16, 128
dangers 17
exchange traded 12, 14
exposure 31
and financial crisis 4–5, 8–9, 10
funding 335–41
Lehman experience 17
market participants 15–16
market size 12–14
users 11
see also over-the-counter (OTC) derivatives
discounting 291–2, 313–14
OIS discounting 295–6
OIS rates 292
and perfect collateralisation 294–5
risk-free rate 293–4
discretisation 250–1, 256
disputes 81–2, 249–50
dividends 83
Dodd–Frank Wall Street Reform and Consumer Protection Act (2009) 1, 8, 178, 193
doom loop 178, 179
double default 145–6
Downing, C. 268
Drexel Burnham Lambert 62
drift 218, 219–20, 223
dual curve discounting 296
Duffee, G.R. 379
Duffie, D. 390
DVA see debt value adjustment

EAD see exposure at default
EBA see European Banking Authority
EE see expected exposure
effective expected positive exposure (EEPE) 118–19, 408–9
EFV see expected future value
EIM see expected IM
Elliott, D. 194n
EMIR see European Market Infrastructure Regulation
dead-users 31–2, 38, 100
enhanced supplementary leverage ratio 181
EONIA (euro overnight index average) 83, 292, 304
EPE see expected positive exposure
ES see expected shortfall
European Banking Authority (EBA) 174, 176, 177n, 179, 182, 261, 275
European Market Infrastructure Regulation (EMIR) 8, 82
European Commission 193
exotic products 213–14, 323
expected exposure (EE) 116–17, 172, 236, 240–1, 301, 330, 370
expected future value (EFV) 114–15, 123–4, 338, 341
expected IM (EIM) 364
expected positive exposure (EPE) 117–18
stressed 163
expected shortfall (ES) 22, 180
exposure see credit exposure
exposure at default (EAD) 145, 146–8, 167
comparison of methods 157–61
methods for computing 147
fair value 4, 326
Fannie Mae 5, 6, 8, 92, 191
FAS see Financial Accounting Standards Board

FASB see Financial Accounting Standards Board
FBA see funding benefit adjustment
FCA see funding cost adjustment
Fed Funds (USA) 83, 292, 293, 304
Federal Reserve Bank of New York 3, 7
Financial Accounting Standards Board (FASB) 333
Financial Accounting Standards (FAS), FAS 157 (Fair Value Measurement) 4–5, 8, 40, 326
financial statements 339–41
Finac 416
Finger, C. 388
Fleck, M. 386
capital floors 181–2
Fons, J.S. 268
foreign exchange (FX) 18, 50, 120, 155, 226, 370
forward products 378
rates 219
risk 11
settlement risk 27–8
wrong-way collateral 382
forward rate agreements (FRAs) 120
forward rates 115
FRAs see forward rate agreements
Freddie Mac 5, 6, 8, 92, 191
front-office 414, 415
FRTB see fundamental review of the trading book
FTP see funds transfer pricing
Fuji, M. 307
fundamental review of the trading book (FRTB) 22, 180
funding 43, 422
costs 33
differences with credit exposure 136
exposure 138–40
liquidity risk 98–100, 107–8, 261–2, 288
funding benefit adjustment (FBA) 338–9, 342, 344, 346–7, 349, 350, 351, 366, 425
funding cost adjustment (FCA) 338–9, 342, 343, 346, 351, 354, 365, 366, 424, 429
funding costs/benefits 135–6
nature of 336–8
reasons for 335–6
funding curves 285
asset-specific 286
Index  463

bilateral collateral rules 285
clearing mandate 285
defining 286–8
increased capital requirements 285
leverage 285
liquidity coverage ratio 285
net stable funding ratio 285
funding value adjustment (FVA) 2, 10, 44, 71, 73, 83, 100, 135, 203, 286, 298, 326, 375, 401
allocation 348
complex cases 345–7
contingent 347–8
costs/benefits 335–8
CVA/DVA/FVA framework 350–1
defining funding rate 351–2
discounting approach 343–5
example 356–7
in financial statements 339–41
Hull & White and accounting arguments 352–4
intuitive definition 341–3
link to debt value adjustment (DVA) 349
opposing views 355–6
relationship to CVA and DVA 338–9
resolving the debate 354–5
as symmetric 351
funds transfer pricing (FTP) 286
future uncertainty 120
FVA see funding value adjustment
FX see foreign exchange

G-Sifis see globally systemically important financial institutions
gaming 320
gap risk 74
Garcia-Cespedes, J.C. 385
generic curve construction
cross-sectional approach 283–4
general approach 280–1
hedging 284
mapping approach 282–3
third party curves 281–2
generic proxies 279
gentleman’s agreement 305
Germany 390
Gibson, M. 257, 394
Giesecke, K. 268
Glasserman, P. 214
global financial crisis 277
background 1–2
backlash/criticisms 8–9
in practice 5–8
pre-crisis 3–5
regulatory reform 8
results of 10
globally systemically important financial institutions (G-Sifis) 96
Goldman Sachs 7
Gordy, M. 144
grace period 95
Greeks 413, 414
Green, A. 178, 288, 367, 374, 375
Gregory, J. 101, 202, 236, 329
Group of Ten (G10) countries 3
Group of Twenty (G20) countries 4, 8
guarantees 186
haircuts 75–7, 104, 261, 307
hazard rate approaches 383–5
hedging 28, 29, 32, 275–6, 284, 374–5, 423
capital relief 372, 407–10
counterparty risk 41–2
credit, collateral, funding, capital costs 404
cross-dependency 404
debt value adjustment 332–3
documentation 404
index CDS 406
market practice 411–12
single-name CDS 406
single-name proxy CDS 406
xVA 403–12
high quality liquid assets (HQLAs) 182
Hille, C.T. 128
HQLAs see high quality liquid assets
hurdles 398–9
transacting within 423
Iabichino, S. 351
IAS see International Accountancy Standards
IBM 416
IFRS see International Financial Reporting Standards
IM see initial margin
IMF see International Monetary Fund
IMM see internal model method
Implied Swap Adjustment (ISA) Mechanism 89
incremental CVA 317–19
incremental exposure 235–6, 237–40
incremental risk charge (IRC) 174n
initial margin (IM) 74, 88, 94, 159–60, 324–5, 359–60, 430–3
bilateral 360
calculations 105–6
contingent posting 360
dynamic 263–4
funding exposure 264–5
impact on exposure 262
profiles 361–4
segregation 264–5
intermediation 337, 437–8
internal model method (IMM) 147, 148, 173, 180, 217, 370, 373–4, 408, 418–19, 434
alpha factor 151–3
approval 418–19
background 151
backtesting 162
CVA capital charge 162
effective expected positive exposure (EEPE) 151–3
increased MPR 162
stressed EPE 162
internal ratings-based approach (IRB) 144–5, 201
International Accountancy Standards, IAS 39 (Financial Instruments: Recognition and Measurement) 4, 8
International Financial Reporting Standards (IFRS), IFRS 13 accounting guidelines 8, 9, 40, 270, 326–7
International Monetary Fund (IMF) 7
International Swaps and Derivatives Association (ISDA) 48, 82, 83, 176, 193
IRC see incremental risk charge
ISA see Implied Swap Adjustment (ISA) Mechanism
Iscoe, I. 386
ISDA 2013 EMIR Portfolio Reconciliation, Dispute Resolution and Disclosure Protocol 82
ISDA see International Swaps and Derivatives Association
ISDA Master Agreement 49, 51, 53, 53–4, 61, 62
ISDA Resolution Stay Protocol 96
iTraxx 276, 278, 283
Jamshidian, F. 313
Jarrow, R.A. 309, 390
Jorion, P. 220, 236
JP Morgan Chase 6, 341
jump approaches 388–90
Kaufman, G.G. 90
Kenyon, 178, 288, 296, 367, 374
KfW Bankengruppe 50–1
Kjaer, M. 341, 351, 353, 355
Kroszner, R. 188
Kupiec, P. 165n
KVA see capital value adjustment
large homogeneous pool (LHP) 144
Laughton, S. 353
LCH.Clearnet 193
LCR see liquidity coverage ratio
legal risk 19, 69, 97
legal/operational efficiency 200
Lehman Brothers 1, 6–7, 8, 9, 10, 12, 17, 50, 50–1, 54, 62, 86, 191, 193, 249, 327
Lehman Brothers Financial Products 189
lending risk 25–6
leverage 8
leverage ratio (LR) 1, 8, 180–1, 285, 367
Levin, R. 379, 388
Levy, A. 379, 388
LGD see loss given default
LIBOR see London Interbank Offered Rate
Lipton, A. 390
liquidation of collateral 95
liquidity 8, 200, 275, 277–8
buffer 261, 361
risk 1, 20, 28, 29, 69, 98–100
liquidity coverage ratio (LCR) 1, 8, 182, 285, 360
liquidity value adjustment (LVA) 354
loans 119
Lomibao, D. 323
London Interbank Offered Rate (LIBOR) 10, 292, 293–4, 296, 336, 344, 351, 354
Long-Term Capital Management (LTCM) 3, 12, 98
Longstaffe, F.A. 214, 268
look-back period 362, 363
look-back points 211
lookup tables 401
loss given default (LGD) 35–6, 172, 201, 273–5, 277, 278, 328
loss method 53, 54
loss mutualisation 200
loss waterfall 196–7
LR see leverage ratio
LTCM see Long-Term Capital Management
LVA see liquidity value adjustment

MacKenzie, D. 23
mapping approach 282–3
margin period of risk (MPR) 56, 94, 134, 156, 246, 345–6, 424
cashflows 250–1
conditionality 249
discretisation 250–1
disputes 249–50
impact 324
increased (Basel III) 162, 163–4
modelling 251
operational risk 97
post-default 95–6
pre-default 95
margin value adjustment (MVA) 2, 10, 45, 100, 182, 203, 285, 286, 298, 336, 360, 373–4, 401, 426, 431, 433, 440
formula 364–6
marginal CVA 319–21
marginal exposure 236, 237, 240–3
mark-to-market (MTM) 13, 28, 31, 32, 33, 52, 56, 58, 64–5, 69, 71, 73, 78–9, 111, 124, 132, 135, 154, 157, 191, 206, 214, 217, 245, 270, 286, 339, 369
funding costs/benefits 336–7
funding value adjustment 336–7
negative 301–2, 304
perfect collateralisation 294–5
positive 304
market cost of funding 355
market participants 14–15
end-user 15–16
large players 15
medium-sized players 15
market quotation 53–4, 329
market risk 18–19, 28, 69, 94–6, 393, 405–6, 407, 411
correlation 405

correlation 405
spot/forward rates 405
volatility 405
market risk capital 359
Markit Analytics 416
Markit sector curves 281
Markit Totem 424–5
Masetti, M. 318
maturity 157–8, 436–7
MBIA 191, 192
Mercurio, F. 296
Merrill Lynch 7, 191
Merton, R. 3
MF Global 86, 97, 98
minimum transfer amount (MTA) 74–5, 251, 295
monolines 6, 190–2
Monte Carlo simulations 172, 206, 209, 318, 322, 364, 368
aggregation 215
extraction 216
model 210–11
post-processing 215–16
revaluation 212–15
scenario generation 211–12
moral hazard 187, 200
Morini, M. 296, 329, 349
mortgage-backed securities (MBSs) 5
mortgages 69
MPR see margin period of risk
MTA see minimum transfer amount
MTM see mark-to-market
multilateral netting 56–7
Murex 416
Murphy, D. 178
mutual puts 63
MVA see margin value adjustment

NEE see negative expected exposure
negative drift 124
negative expected exposure (NEE) 118, 122–3, 235, 330, 334, 345
negative feedback loops 178
negative MTM 153, 157, 159
net gross ratio (NGR) 150, 155
net independent collateral amount (NICA) 156
net stable funding ratio (NSFR) 1, 182, 285
netting 27, 28, 47–8, 52, 136, 160–1
bilateral 52
close-out 33, 51–2, 53
netting (continued)
cross-product 52–3
current exposure method (CEM) 149–50
impact 55–6, 129–32
and incremental CVA 317–19
multilateral 56–7
payment 50–1
in SA-CCR 155
netting benefits 228–34
allocating 235–43
NFC see non-financial counterparty
NGR see net gross ratio
NICA see net independent collateral amount
non rehypothecation and segregation 335
non-cash collateral 92, 260–1, 307
non-financial counterparty (NFC) 179n
donvation 332, 337
NSFR see net stable funding ratio
Numerix 416

off-market transaction 157, 427–8
OIS see overnight indexed spread
O’Kane, D. 59
one-way collateral agreement 298, 429–30
operational risk 19, 28, 29, 69, 96–7
optionality 126–7
OTC see over-the-counter
over-the-counter (OTC) derivatives 1, 2, 3, 8, 10, 12, 193
bilateral 57–8, 70, 84, 153
bilateral netting 52
capital costs 288–9
centrally cleared 13–14
clearing 193–5
collateralised 14, 69, 98
counterparty risk 185
derivative documentation 49
economic costs 43–4
end-user 99
market players 15–16
market size 12–14
product type 29–30
uncollateralised 14, 203
see also derivatives
overcollateralisation (initial margins) 9, 74, 135, 157, 430–3
overnight indexed spread (OIS) 10, 83, 89, 286, 344
discounting 295–6, 310

methodology 296
rates 292
risk-free rate 293–4

P&L explain 407
P-measure 217
partially collateralised 135
pathwise approach 212
payer swap 121
payment netting 48, 50–1
payment vs payment (PVP) 50
perfect collateralisation
and discounting 294–5
push towards 297
xVA terms 297–9
periodic cashflows 120–5
PFE see potential future exposure
Pindyck, R. 227
Piterbarg, V. 294, 307, 341
post-processing 215–16
potential future exposure (PFE) 38, 115, 116–17, 149, 150, 155, 201, 211, 214, 367
Prampolini, A. 296, 349
pre-settlement risk 26
Pricing Partners 416
procyclicality 177, 201
prudent value 182–3
PVP see payment vs payment
Pykhtin, M. 148, 212, 236, 249, 393, 409

Q-measure 217
QCCPs see qualifying CCPs
qualifying CCPs (QCCPs) 201–2
Quantifi Solutions 416
quantifying exposure 205
allocating exposure 235–43
choice of model 222–8
examples 229–34
Monte Carlo simulation 209, 210–16
parametric approaches 205–6
real-world/risk neutral methods 216–22
semi-analytical methods 206–9
quanto effect 389
ratings 77–8, 281
real-world vs risk-neutral 216–18
Rebonato, R. 172
reconciliations 81–2
recovery impact on CVA 316–17
Index 467

recovery rates 35–6
recovery values 274
regulatory capital 359, 404, 414, 415
  methodology 372
regulatory collateral rules 100–1
  covered entities 101
  general requirements 102–4
  haircuts 104
  initial margin calculations 105–6
  rehypothecation 105
  segregation 105
  standardised initial margin method (SIMM)
  106–7
rehypothecation 85–7, 105
  impact 136–8
remuneration (of collateral) 83
replacement cost 33, 53–4
reset agreements 64–5
restrikes 337, 438–9
return on capital (ROC) 288, 375
return on equity (ROE) 405
revaluation 212–15
right-way risk 377, 381, 385
risk weighted asset (RWA) 144
risk-free rate 10, 294, 351, 390–1
risk-neutral 39–40, 121, 216–17, 314, 349, 354,
  370
  see also real-world vs risk-neutral
risk-neutral default probabilities
  definition 271–2
  derivation 267
  move to risk-neutral 269–70
  vs real-world default probability 267–8
RiskMetrics 416
ROC see return on capital
ROE see return on equity
roll-off risk 211, 212
Rosen, D. 236, 386
SA-CCR see standardised approach for
counterparty credit risk
Saunders, D. 386
SBA see sensitivity-based approach
scenario generation 211–12
Schmidt, A. 386
Scholes, M. 3
Schwartz, S.E. 214
SCSA see Standard Credit Support Annex
security transfer 82–3
segregation 87–8, 105, 136, 264–5
  impact 136–8
semi-analytical methods 206–7, 314–15
sensitivity-based approach (SBA) 107
Sepp, A. 390
set-off 53
settled recovery 274
settlement risk 26–8
SIFIs see systematically important financial
  institutions
SIMM see standardised initial margin method
simulation engines 412
simulation model 210–11
single-name proxy 276, 278–9
Singleton, K.J. 390
skin in the game 197
SM see standardised method
Sokol, A. 227, 249, 393
Sorenson, E.H. 206
Sorenson–Bollier analogy 403
sovereigns, supranations and agencies (SSA)
  138
SPE see special purpose entity
special purpose entity (SPE) 187–8
special purpose vehicles (SPVs) 6, 186, 187–8
square root of time 120, 249
SSA see sovereigns, supranations and
  agencies
Standard & Poor’s 189, 282
Standard Credit Support Annex (SCSA) 89
standardisation of derivative contracts 58–61
standardised approach 144
standardised approach for counterparty credit
  risk (SA-CCR) 2, 147, 148, 205–6, 368,
  369, 418, 426
  background 153–4
  basic approach 154
  collateral 156–7
  negative MTM 157
  netting 155
  overcollateralisation 157
standardised formula 169–71
standardised initial margin method (SIMM)
  106–7, 359–60
standardised method (SM) 147
stress-testing 162, 167–8, 413
stressed EPE 163
structural approaches 385–6
sub-additivity 22
substitution 84–5, 145
Sundaram, R. 226
SunGard 416
swap rate 121
swaption 126–7, 207
symmetric funding 350
systemic risk 29
systemically important financial institutions (SIFIs) 187
T-forward measure 313
Takahashi, A. 307
Tang, Y. 349
tear-up features 61–2
term structure 272–3
termination clauses 29, 33
third-party valuation 82
threshold 73, 159–60, 324–5
time horizon 113, 226, 362, 364
title transfer 83
too big to fail 1, 7, 187
Totem see Markit Totem
trade compression 56
bilateral services 57–8
examples 58–61
standardisation 58
transfer price 310, 398
TriOptima 57, 416
Troubled Asset Relief Program (TARP) 7
Turnbull, S.M. 309
two-way collateral agreements 258–60
uncollateralised transaction 298, 433, 439–40
undercollateralisation 73, 335
unwinds 332
Vaisbrot, A. 353
valuation agent 81–2
value-at-risk (VAR) 20–3, 74, 113–14, 174, 180, 197, 217, 362
and backtesting 164–5
correlation/dependency 23–4
models 23
VAR see value-at-risk
variation margin 69–70, 88, 94
Vasicek, O. 144
vendors 416–18
volatility 218, 220, 223
volatility adjusted collateral 150
WACC see weighted average cost of capital
walkaway features 61–2
warehouse approach 400
weaknesses in credit ratings 63
weighted average cost of capital (WACC) 288
White, A. 339, 352–3, 386, 387
Wilde, T. 151
Williams, A. 349
work-out process 402
wrong-way collateral 382–3
wrong-way risk (WWR) 28, 69, 162, 166–7, 377, 400
and central clearing 393–4
challenges 380
classic example 378–9
and collateral 391–3
credit derivatives 390–1
and credit value adjustment (CVA) 380–1
empirical evidence 378–9
general 166
general/specific 379
hazard rate approaches 383–5
jump approaches 388–90
overview 377–80
parametric approach 386–8
quantification 380–3
simple example 377–8, 381–2
specific 166
structural approaches 385–6
WWR see wrong-way risk
xVA 2
assumptions 425–6
birth of 3–46
and central clearing 202–3
different types/examples of impact 291–375
as exotic option 403–4
funding 406
future prospects 443–4
general approach 422–4
hedging 403–12, 411–12
market practice 411–12
market risk 405–6
misalignment 404–5
mitigating counterparty risk/underling
regulatory requirements 47–203
motivation 403
P&L explain 407
quantification of key components 205–89
terms 44–6, 297–9, 446  
xVA desk 42  
capital 398  
collateral optimisation 398  
counterparty risk 398  
funding and margin 398  
hurdles 398–9  
management 397–8  
motivation 397–8  
operation and rollout 400–3  
pricing 397  
profit centre or utility 399–400  
role 397–403, 398–9  
transfer pricing 398  
xVA optimisation 437  
backloading to a CCP 440–1  
costs 433–7  
examples 425–33  
intermediation 437–8  
market practice 422–5  
overview 421–2  
restrikes 438–9  
uncollateralised to collateralised 439–40  
xVA systems  
adjoint algorithmic differentiation 414  
American Monte Carlo 413–14  
backtesting 413  
collateral 413  
data 412  
Greeks 413  
IMM approval 418–19  
optimisations 413–14  
overview 412–13  
pre-calculations 413  
processors 414  
reporting 413  
revaluation functionality 412–13  
risk & regulatory cf front-office requirements 415  
shared/separate implementations 414, 416  
simulation engines 412  
strengths/weaknesses 415  
stress testing 413  
vendor system 416–18  
Yu, B. 214  
Yu, F. 390  
Zhu, S. 212, 323  
Zhu, Y. 313